This article reviews the genetic data on epigenetic modifying mutations in myeloproliferative neoplasms and their clinical implications, preclinical studies exploring our current understanding of how mutations in epigenetic modifying proteins cooperate with myeloproliferative neoplasms drivers to promote disease progression, and recent advances in novel therapeutics supporting the role of targeting epigenetic pathways to treat fibrotic progression.
Keywords: Epigenetic pathways; Epigenetics of MPN; Fibrotic progression; Myelofibrosis; Myeloproliferative neoplasms; Preclinical studies.
Copyright © 2021 Elsevier Inc. All rights reserved.